Key result
Transcatheter tricuspid valve interventions are emerging therapies for severe tricuspid regurgitation, which when progressing post-TAVR increases all-cause death risk fourfold (HR 4.08).
Why the study?
The success of TAVR has highlighted concurrent tricuspid valve disease and the inadequacy of current treatments.
This review highlights the clinical impact of persistent tricuspid regurgitation following TAVR and summarizes the emerging transcatheter therapies that may offer safe and effective treatment options for these high-risk patients.
Transcatheter aortic valve replacement (TAVR) has revolutionized the management of aortic valve disease. However, its success has brought attention to concurrent tricuspid valve disease and the inadequacy of treatments. This review explores the emerging field of transcatheter tricuspid valve interventions (TTVI) after TAVR. We address the pathophysiology and prevalence of post-TAVR tricuspid valve disease and TTVI strategies, including repair, replacement, annuloplasty, and edge-to-edge repair. We also discuss clinical studies assessing TTVI safety and efficacy, including for patients with previous TAVR. Collaboration among clinical disciplines remains crucial for advancing this emerging field to establish best practices regarding patient selection and procedural complexities.
No takes yet. Share an insight, caveat, or question.
Silkowski et al. (2024) conducted a review in Functional Tricuspid Regurgitation post-Transcatheter Aortic Valve Replacement. Transcatheter tricuspid valve interventions (TTVI) was evaluated. Transcatheter tricuspid valve interventions are emerging therapies for severe tricuspid regurgitation, which when progressing post-TAVR increases all-cause death risk fourfold (HR 4.08).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: